Artwork

Ira Pastor에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Ira Pastor 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!

Dr. Mads Krogsgaard Thomsen, CEO, Novo Nordisk Foundation - Improving People’s Lives Globally

31:33
 
공유
 

Manage episode 317180151 series 2835025
Ira Pastor에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Ira Pastor 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Dr. Mads Krogsgaard Thomsen, DVM, DSc., Ph.D., is the CEO of the Novo Nordisk Foundation (https://novonordiskfonden.dk/), an international foundation with a dual objective: to provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group (of which Novo Nordisk A/S is the largest holdings) and to support scientific, humanitarian and social purposes. In 2020, the Novo Nordisk Foundation had a net worth of US$73.1 billion, making it the largest financial endowment in the world. Novo Nordisk Foundation owns Novo Holdings A/S, a holding company and majority shareholder of Novo Nordisk, as well as Novozymes, a global biotechnology company focused on the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The foundation is also a major shareholder in more than 75 other companies. Originally, trained as a veterinarian / DVM at The Royal Veterinary and Agricultural University (now part of the University of Copenhagen), where he also holds a DSc. in this domain, Dr. Thomsen started his career as a PhD pharmacology student at the University of Copenhagen, after which he worked three years as a researcher at LEO Pharma. Thirty years ago, he joined Novo Nordisk, initially as Head of Growth Hormone Research and subsequently as Senior Vice President of Diabetes R&D. In 1995, he was appointed Senior Vice President of Discovery and in 2000, he became Executive Vice President of Research & Development/Chief Scientific Officer. Over the years, he has headed the development of 20 medical drugs, especially within diabetes treatment and the groundbreaking development of GLP-1 technologies. Dr. Thomsen has served as President of the Danish Academy of Technical Sciences and Chairman of the Board of the University of Copenhagen, where he is also an adjunct professor of Pharmacology.

Support the show

  continue reading

502 에피소드

Artwork
icon공유
 
Manage episode 317180151 series 2835025
Ira Pastor에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Ira Pastor 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.

Dr. Mads Krogsgaard Thomsen, DVM, DSc., Ph.D., is the CEO of the Novo Nordisk Foundation (https://novonordiskfonden.dk/), an international foundation with a dual objective: to provide a stable basis for the commercial and research activities conducted by the companies within the Novo Group (of which Novo Nordisk A/S is the largest holdings) and to support scientific, humanitarian and social purposes. In 2020, the Novo Nordisk Foundation had a net worth of US$73.1 billion, making it the largest financial endowment in the world. Novo Nordisk Foundation owns Novo Holdings A/S, a holding company and majority shareholder of Novo Nordisk, as well as Novozymes, a global biotechnology company focused on the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The foundation is also a major shareholder in more than 75 other companies. Originally, trained as a veterinarian / DVM at The Royal Veterinary and Agricultural University (now part of the University of Copenhagen), where he also holds a DSc. in this domain, Dr. Thomsen started his career as a PhD pharmacology student at the University of Copenhagen, after which he worked three years as a researcher at LEO Pharma. Thirty years ago, he joined Novo Nordisk, initially as Head of Growth Hormone Research and subsequently as Senior Vice President of Diabetes R&D. In 1995, he was appointed Senior Vice President of Discovery and in 2000, he became Executive Vice President of Research & Development/Chief Scientific Officer. Over the years, he has headed the development of 20 medical drugs, especially within diabetes treatment and the groundbreaking development of GLP-1 technologies. Dr. Thomsen has served as President of the Danish Academy of Technical Sciences and Chairman of the Board of the University of Copenhagen, where he is also an adjunct professor of Pharmacology.

Support the show

  continue reading

502 에피소드

모든 에피소드

×
 
Loading …

플레이어 FM에 오신것을 환영합니다!

플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.

 

빠른 참조 가이드